Biohaven Pharmaceutical Holding Co Ltd

Biohaven Pharmaceutical — Technical Presentation (May 2019)

35 slides from Biohaven Pharmaceutical's technical presentation, May 8, 2019

  1. Slide 1: Disclaimer

    Disclaimer This presentation contains forward-looking statements within the meaning of “safe harbor” provisions of The Private Securities Litigation Reform Act of 1995, including: statements about our plans to develop and commercialize our product candidates, our planned clinical trials for our rime

  2. Slide 2: Neuroinnovating across three novel small-molecule platforms

    NEUROINNOVATING ACROSS THREE NOVEL SMALL-MOLECULE PLATFORMS BROAD PIPELINE OF LATE STAGE PRODUCT CANDIDATES

  3. Slide 3: Biohaven's Late Stage Development Pipeline

    Biohaven’s Late Stage Development Pipeline RIMEGEPANT Phase 3 Zydis™ ODT Acute Migraine RIMEGEPANT Phase 3 Acute Migraine RIMEGEPANT Phase 3 Long-Term Safety Study CGRP antagonism RIMEGEPANT Phase 3 Preventive Migraine TRORILUZOLE Phase 2/3 Alzheimer’s Disease (AD)† TRORILUZOLE Phase 2/3 Obsessive-C

  4. Slide 4: NOjeCTION CGRP-Antagonist Platform: Expanded Phase 3 Data, Panel Discussion and Q&A

    NOjeCTION CGRP-Antagonist Platform TM Expanded Phase 3 Data, Panel Discussion and Q&A Moderator: Kishen Mehta

  5. Slide 5: Richard Lipton, MD

    Richard Lipton, MD ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 6 Edwin S. Lowe Professor and Vice Chair of Neurology Professor of Epidemiology and Population Health, Psychiatry and Behavioral Science, Albert Einstein College of Medicine Director, Montefiore Headache Center Fellow, Ameri

  6. Slide 6: David Kudrow, MD

    David Kudrow, MD MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 7 Headache Specialist, Board Certified Neurologist - Director, California Medical Clinic for Headache Director Emeritus, Headache Clinic Harbor-UCLA Medical Center Assistant Clinical Professor in Neurology, UCLA David

  7. Slide 7: Jelena Pavlovic, MD, PhD

    Jelena Pavlovic, MD, PhD MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 8 Headache specialist, Neurologist, Montefiore Medical Center PhD in Molecular Biology Assistant professor of Neurology, Albert Einstein College of Medicine Board certified in Neurology Member, American Academ

  8. Slide 8: Rimegepant 75 mg Zydis ODT Phase 3 Results in Acute Treatment of Migraine

    Rimegepant 75 mg Zydis® ODT Phase 3 Results: Study 303 in the Acute Treatment of Migraine

  9. Slide 9: Study Design: Phase 3 Rimegepant 75 mg Zydis ODT (Study 303)

    Study Design: Phase 3 Rimegepant 75 mg Zydis ODT (Study 3031) MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 10 RIMEGEPANT Phase 3 – Study 303, 75 mg ZYDIS ODT Objective: Assess Rimegepant Zydis ODT versus Placebo on efficacy, safety, and tolerability in the acute treatment of mig

  10. Slide 10: Demographics: Representative of Typical Migraine Patient Population

    RIMEGEPANT Phase 3 – Study 303, 75 mg ZYDIS ODT Demographics: Representative of Typical Migraine Patient Population MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 11 Characteristic Overall (N=1351) Age, years, mean (SD) 40.2 (12.0) Sex, n (%) Female 1147 (84.9) Male 204 (15.1) Mea

  11. Slide 11: Rimegepant Zydis ODT Superiority Over Placebo on Hierarchically-Tested Endpoints

    MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 12 Rimegepant Zydis ODT Superiority Over Placebo on 21 Consecutive, Prespecified, Hierarchically-Tested Efficacy Outcome Measures Co-Primary and Secondary Endpoints Rimegepant N=669 Placebo N=682 P value Pain freedom, 2 h (co-primary)

  12. Slide 12: Efficacy Highlights: Single Dose Rimegepant Zydis ODT

    RIMEGEPANT Phase 3 – Study 303, 75 mg ZYDIS ODT MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 13 Efficacy Highlights: Single Dose Rimegepant Zydis ODT Shows Early and Sustained Effects on Pain and Return to Normal Functioning Pain Relief *60 min *90 min *2 hr *24 hr *48 hr Sustai

  13. Slide 13: Nausea Freedom at 2 Hours Post-Dose in Pooled Analysis

    RIMEGEPANT PHASE 3 – Studies 301, 302 (75 mg Tablet) & 303 (75 mg Zydis ODT) Nausea Freedom at 2 Hours Post-Dose is Significant in Pooled Analysis 24 hr 48 hr MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 14 Data were analyzed using Cochran-Mantel Haenszel methods. Individual stu

  14. Slide 14: Pain Relief: Early Separation From Placebo

    RIMEGEPANT Phase 3 – Study 303, 75 mg ZYDIS ODT Pain Relief: Rimegepant Zydis ODT Shows Early Separation From Placebo Beginning within 15 Minutes and is Statistically Significant by 60 Minutes MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 1. Pain Relief is defined as patients who

  15. Slide 15: 24-48 hr Pain Relief: Lasting Benefit with a Single Dose

    Single Dose of Rimegepant, No Rescue Meds RIMEGEPANT Phase 3 – Study 303, 75 mg ZYDIS ODT 24-48 hr Pain Relief: Rimegepant Shows Lasting Benefit with a Single Dose Sustained Pain Relief Rimegepant n=669 Placebo n=682 p-value 2 to 24 hrs 47.8% 27.7% <0.0001 3 to 24 hrs 56.4% 33.1% <0.0001 4 to 24 hrs

  16. Slide 16: Pain Freedom: Significant Separation at 2 hrs

    RIMEGEPANT Phase 3 – Study 303, 75 mg ZYDIS ODT Pain Freedom: Rimegepant Demonstrates Significant Separation at 2 hrs and Increasing Benefit Over Time After a Single Dose MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES Single Dose of Rimegepant, No Rescue Meds % of Patients Pain Fr

  17. Slide 17: Rescue Medication Use

    RIMEGEPANT Phase 3 – Study 303, 75 mg ZYDIS ODT Rescue Medication Use: Rimegepant Treated Patients Had Lower Use of Rescue Meds and Delayed Time to Use Data are Kaplan-Meier estimates of Rescue Medicine Use; subjects were censored (not included) at the time of taking rescue medication, and those los

  18. Slide 18: Safety: Rimegepant 75 mg ODT Well Tolerated and Similar to Placebo

    RIMEGEPANT Phase 3 – Study 303, 75 mg ZYDIS ODT Safety: Rimegepant 75 mg ODT was Well Tolerated and Similar to Placebo MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 19 The most common AEs were nausea and urinary tract infection (<1.6%) There were no treatment-related increases in

  19. Slide 19: Summary: Rimegepant 75 mg ODT Profile of Rapid and Sustained Effect

    RIMEGEPANT Phase 3 – Study 303, 75 mg ZYDIS ODT Summary: Rimegepant 75 mg ODT – Profile of Rapid and Sustained Effect in the Acute Treatment of Migraine MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 20 Rapid onset of pain relief with single dose Numerical separation from placebo

  20. Slide 20: Rimegepant Value Proposition: "One and Done"

    Rimegepant Value Proposition: “One and Done” MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 21 Rapid Pain Relief Zydis® ODT Durable Benefits through 48 hrs Placebo-like Tolerability

  21. Slide 21: Rimegepant 75 mg Open-Label Long-Term Safety Study

    Rimegepant 75 mg Open-Label Long-Term Safety Study

  22. Slide 22: Long Term Safety Study 201: Study Design

    RIMEGEPANT LONG TERM SAFETY – Study 201 Study Design: Rimegepant 75 mg Open Label Long-Term Safety MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 23 AS-NEEDED up to 52 weeks (up to 1x/daily dosing) FIXED-DOSING up to 12 weeks (QOD+PRN dosing) Observation Period 30 days Rimegepant

  23. Slide 23: Long Term Safety Study 201: Interim Analysis, Overall LFT Results

    RIMEGEPANT LONG TERM SAFETY – Study 201, Interim analysis 21FEB2019 MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 24 105,192 doses of rimegepant 75 mg administered across 1,784 patients with migraine Median number of days in study 278 Interim hepatic data were reviewed by an exte

  24. Slide 24: Fixed-Dosing Cohort LFT Results

    RIMEGEPANT (BHV-3000) LONG TERM SAFETY STUDY – Study 201, Interim analysis 21FEB2019 MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 25 Subjects in the 12-week QOD+PRN cohort (n=286) were exposed to 11,296 rimegepant 75 mg tablets Median number of tablets per 4 week period 14.2 Med

  25. Slide 25: No Liver Signal Detected in Fixed-Dosing Cohort

    RIMEGEPANT LONG TERM SAFETY – Study 201, Interim analysis 21FEB2019, ON-TREATMENT CENTRAL LABS No Liver Signal Detected in Fixed-Dosing (QOD+PRN) Cohort ALT or AST Rimegepant N=286 > 3x ULN 0 > 5x ULN 0 > 10x ULN 0 > 20x ULN 0 Total Bilirubin > 2x ULN 0 Alkaline Phosphatase > 2x ULN 0 LFT Results fr

  26. Slide 26: Rimegepant Shows Reduction in Migraine Days

    RIMEGEPANT LONG-TERM SAFETY – Study 201, Interim analysis 21FEB2019 Rimegepant Shows Reduction in Migraine Days All Subjects with > 14 Migraine Days/Mo During Observation Period MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 27 Subjects with > 14 migraine days/mo baseline, show re

  27. Slide 27: Fixed-Dosing Cohort Shows Robust Reduction in Moderate-Severe Migraine Days

    48.4% of subjects in the fixed-dosing QOD+PRN cohort experienced >50% reduction from baseline during month 3 in the frequency of monthly migraine days with moderate-to-severe pain intensity RIMEGEPANT LONG TERM SAFETY STUDY – Study 201 Rimegepant Fixed-Dosing Cohort Shows Robust Reduction in Moderat

  28. Slide 28: Prevention Strategy: Redefine the Treatment Paradigm as a Continuum

    Prevention Strategy: Redefine the Treatment Paradigm as a Continuum MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 30 Rimegepant acute efficacy and long-duration of action established in three Phase 3 Trials Early signals from 201 data suggest that Rimegepant has the potential for

  29. Slide 29: Clinical Case Reports: Oral Rimegepant for Breakthrough Migraine Attacks in Patients on CGRP mAb

    Clinical Case Reports: Use of Oral Rimegepant for Treatment of Breakthrough Migraine Attacks in Patients on CGRP Monoclonal Antibody

  30. Slide 30: Background: Case Reports of Concomitant Use of Oral Rimegepant With CGRP mAb

    Background: 2 Case Reports of Concomitant Use of Oral Rimegepant With Injectable CGRP Monoclonal Antibody MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 32 CGRP has been confirmed as a therapeutic target in migraine: While injectable CGRP mAbs have demonstrated efficacy in reducin

  31. Slide 31: Background: Case Reports (Cont'd)

    Background: 2 Case Reports of Concomitant Use of Oral Rimegepant With Injectable CGRP Monoclonal Antibody (Cont’d) MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 33 Case reports are presented of 2 patients with historically high migraine frequency participating in the long-term sa

  32. Slide 32: Case Study 1: Rimegepant with Preventive Erenumab

    44-year-old white female with a 22-year history of migraine Enrolled in Study 201 (LT Safety) 10 attacks during 1 month run-in Post FDA approval started erenumab (CGRP receptor-targeting mAb) Patient Profile Case Study 1: Oral Rimegepant is Safe and Consistently Effective for Acute Treatment of Brea

  33. Slide 33: Case Study 2: Rimegepant added to Preventive Fremanezumab

    47-year-old white female with a 33-year history of migraine On fremanezumab 225 mg/month for 2 months (CGRP ligand-targeting mAb) Enrolled in Study 201 (LT Safety) 11 attacks during 1 month run-in Patient Profile Case Study 2: Oral Rimegepant is Safe and Effective for Acute Treatment of Breakthrough

  34. Slide 34: Summary: Oral Rimegepant in Combination with Injectable CGRP mAbs

    Summary: Oral Rimegepant has the Potential to be Safe and Effective at Treating Breakthrough Migraine Attacks in Combination with Injectable CGRP mAbs Conclusions: To our knowledge, these are the first clinical reports showing that oral rimegepant has the potential to be safe and consistently effect

  35. Slide 35: Summary: Oral Rimegepant in Combination with Injectable CGRP mAbs

    Summary: Oral Rimegepant has the Potential to be Safe and Effective at Treating Breakthrough Migraine Attacks in Combination with Injectable CGRP mAbs Conclusions: + To our knowledge, these are the first clinical reports showing that oral rimegepant has the potential to be safe and consistently effe

Biohaven Pharmaceutical Holding — Technical Presentation (May 2019) on 6ix